Opfolda (Miglustat) Patent Expiration, LOE Window & CMS Spending

Opfolda (Miglustat) by Amicus Therapeutics Us: FDA Orange Book core substance LOE 2035-09-30 (last listed 2038-09-16), 3 AB generics, $54K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAmicus Therapeutics Us
FDA Application & PathwayN215211 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2035-09-30
Last Listed Patent or Exclusivity Date2038-09-16
Orange Book Patents (*PED Extensions)10 patents (0 *PED)
Active AB-Rated Generic Competitors3
2024 CMS Total Public Spend$54K
2024 Medicare Part D Spend$41K
2024 Medicaid Spend$14K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel